Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Operating Expenses: 2011-2024

Historic Operating Expenses for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $1.1 billion.

  • Ptc Therapeutics' Operating Expenses fell 17.23% to $208.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 3.07%. This contributed to the annual value of $1.1 billion for FY2024, which is 19.46% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Operating Expenses is $1.1 billion, which was down 19.46% from $1.4 billion recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Operating Expenses registered a high of $1.4 billion during FY2023, and its lowest value of $812.5 million during FY2020.
  • In the last 3 years, Ptc Therapeutics' Operating Expenses had a median value of $1.1 billion in 2022 and averaged $1.2 billion.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 48.24% in 2020, then decreased by 19.46% in 2024.
  • Ptc Therapeutics' Operating Expenses (Yearly) stood at $812.5 million in 2020, then climbed by 12.37% to $913.0 million in 2021, then rose by 25.54% to $1.1 billion in 2022, then climbed by 20.16% to $1.4 billion in 2023, then dropped by 19.46% to $1.1 billion in 2024.